SSA
ORKA

Schonfeld Strategic Advisors’s Oruka Therapeutics ORKA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,517
Closed -$80K – 1933
2020
Q3 		$80K Buy
+1,517
New +$107K ﹤0.01% 1287

Other funds holding ORKA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Schonfeld Strategic Advisors's ORKA Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of Oruka Therapeutics (ORKA) in Q4 2020, closing a stake of 1,517 shares — an estimated $80K sold.

Schonfeld Strategic Advisors first reported a position in ORKA in Q3 2020 and held it in 1 quarter. The position peaked at $80K in Q3 2020. 20 funds tracked by Wall St. Rank hold ORKA as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining Oruka Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,517 Oruka Therapeutics shares in Q4 2020, an estimated $80K.
  • Schonfeld Strategic Advisors first reported a position in Oruka Therapeutics in Q3 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Oruka Therapeutics position peaked at $80K in Q3 2020.
  • 20 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.